TTP and aHUS in Complicated Pregnancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-21

Study Completion Date

2020-03-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A single site observational study aiming to:

(i) Identify cases of previously undiagnosed thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic syndrome (aHUS) in a cohort of women with complicated pregnancies (ii) Characterise the clinical features of these cases and (ii) Identify clinical features or biomarkers which may help distinguish TTP/aHUS from other complications of pregnancy such as preeclampsia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Obstetric Antiphospholipid Antibody Syndrome : Contribution of the Evaluation of ADAMTS13 Made at the Diagnosis of Pregnancy on Evaluation the Risk of Pre-eclampsia

NCT04319341

Antiphospholipid Antibody Syndrome in Pregnancy

COMPLETED

Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome

NCT03232359

Pre-Eclampsia, Severe HELLP Syndrome Microangiopathy

COMPLETED

Promising Bimarker Prediction of Outcome of HELLP Syndrome.

NCT03246542

Pre-Eclampsia, Severe HELLP Syndrome Microangiopathy

COMPLETED

Promacta Pregnancy Registry

NCT01064336

Purpura, Thrombocytopaenic, Idiopathic

COMPLETED

Neutrophil Extracellular Traps Mediate Antiphospholipid Antibody-induced Pregnancy Loss

NCT03735108

Neutrophil Extracellular Traps; Antiphospholipid Antibody-induced Pregnancy Loss

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombotic Thrombocytopenic Purpura Atypical Hemolytic Uremic Syndrome Pre-Eclampsia HELLP Syndrome Thrombocytopenia IUGR Stillbirth Thrombotic Microangiopathies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ADAMTS 13, complement and angiogenic biomarkers

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Women, either currently pregnant or recently postpartum, and affected by one or more of the following complications in the index pregnancy: (i) Preeclampsia with evidence of end organ damage (renal/ liver/ haematological/ neurological) or uteroplacental dysfunction (FGR/IUFD) (ii) HELLP syndrome (iii) Fetal growth restriction (FGR) (growth \<10th centile) that is unexplained (ie not due to infection, fetal structural anomaly, fetal chromosomal or pre-existing maternal medical problem) (iv) Intrauterine fetal demise (IUFD) after 20 weeks' gestation that is unexplained (v) Unexplained new onset renal impairment (defined by serum creatinine \>85umol/L 1st trimester, or \>80umol/L 2nd trimester, or \>90 umol/L 3rd trimester\[32\]; OR an increase in serum creatinine by (i) at least 1.5 times the baseline or (ii) of equal or greater than 26.5umol/L (as per KDIGO criteria) (vi) Unexplained new onset thrombocytopenia (platelets \<75x10\^9/L)

Exclusion Criteria

* Previous diagnosis of TTP or aHUS
* Known disorder of complement dysregulation
* Patients not wishing to participate
* Patients aged less than 16
* Patients lacking capacity to provide informed consent

Minimum Eligible Age

16 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No